CompletedPhase 4ACTRN12610000016033

The 2VAL Study: A trial comparing the effect of valacyclovir and valganciclovir prophylaxis against cytomegalovirus (CMV) infection after renal transplantation

Randomized trial comparing valacyclovir versus valganciclovir prophylaxis of cytomegalovirus infection in renal transplant recipients

Sponsor

Tomas Reischig, M.D., Ph.D.

Enrollment

114 participants

Start Date

Nov 17, 2007

Study Type

Interventional

Conditions

Cytomegalovirus infection after renal transplantation

Summary

There are two major hypothesis to test: 1) Valacyclovir prophylaxis for cytomegalovirus infection is not inferior than valganciclovir prophylaxis in the prevention of active cytomegalovirus infection and disease. 2) Valacyclovir is superior to valganciclovir in the prevention of indirect effects of cytomegalovirus: acute renal allograft rejection in short term follow up, and renal function and chronic interstitial fibrosis and tubular atrophy (IF/TA) in long-term follow up.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares two antiviral medications, valacyclovir and valganciclovir, for preventing CMV infection after kidney transplant in adults aged 18 and older. It is for transplant recipients where either the donor or recipient has been previously exposed to CMV. People with active viral infections or allergies to the study medications are not eligible.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Oral valacyclovir (VALTREX, Glaxo Wellcome) 8g/day for 3 months after transplantation started within 1 week post transplant

Locations(1)

Czech Republic

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12610000016033

Related Trials

Cytomegalovirus-specific immune monitoring to guide pre-emptive therapy surveillance protocol for prevention of cytomegalovirus infection after renal transplantation.

ACTRN126180009132791 location